JPH10507767A - ロイコトリエン生合成阻害剤としてのビスアリールカルビノール誘導体 - Google Patents
ロイコトリエン生合成阻害剤としてのビスアリールカルビノール誘導体Info
- Publication number
- JPH10507767A JPH10507767A JP8514209A JP51420996A JPH10507767A JP H10507767 A JPH10507767 A JP H10507767A JP 8514209 A JP8514209 A JP 8514209A JP 51420996 A JP51420996 A JP 51420996A JP H10507767 A JPH10507767 A JP H10507767A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- phenol
- lower alkyl
- coumarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 式I: R1R2C(OR3)−Ar1−X−Ar2−Ar3 I 〔式中、Ar1は、1個若しくは2個の同一若しくは異なるR4基で置換された、 0〜3個のNを含む6員芳香環であり; Ar2は、1個若しくは2個の同一若しくは異なるR5基で置換された10員二 環式環(ここで、該二環式環は、0〜4個の環Nを含む二環式芳香環、2H−1 −ベンゾピラン−2−オン又は2H−2−チオキソ−1−ベンゾピランである) であり; Ar3及びAr4は独立に、1個のO若しくはS、及び0−3個のNを含む5員 芳香環;1〜4個のNを含む5員芳香環;又は0〜3個のNを含む6員芳香環( ここで、該芳香環は、1個若しくは2個の同一若しくは異なるR6基で置換され る)であり; Xは、OCH2、CH2O、O、S、S(O)又はS(O)2であり; R1は、H、低級アルキル、低級ペルフルオロアルキル又はAr4であり; R2は、H、低級アルキル又は低級ペルフルオロアルキルであり; R3は、H又は低級アルキルであり; R4は、H、低級アルキル、低級アルコキシ、低級アルキルチオ、NO2、CN 、CF3、CF3O又はハロゲンであり; R5は、R4、オキソ又はチオキソであり; R6は、R4、低級アルキルスルフィニル、低級アルキルスルホニル又はCO2 R7であり; R7は、H又は低級アルキルである〕 を有する化合物又はその医薬上許容し得る塩。 2. Ar1は、それぞれ、1個若しくは2個の同一若しくは異なるR4基で置換 されたPhe又はPyeであり; Ar3は、それぞれ、1個若しくは2個の同一若しくは異なるR6基で置換され た、Ph、Py、Fu、Th、Tz、Im又はPyrであり; Xは、OCH2、CH2O、S、S(O)又はS(O)2であり; R1は、H、低級アルキル、低級ペルフルオロアルキル、Ph、Py、Im、 Fu又はTzであり; 残りの置換基は、請求項1に定義の通りである、請求項1に記載の化合物。 3. Ar1は、それぞれ、置換されていないか、又はハロゲンで置換されたP he又はPyeであり; Ar2は、ナフチル、キノリニル、イソキノリニル又は2H−1−ベンゾピラ ン−2−オン(ここで、ナフチル及びキノリニルは、場合によって、CNで置換 される)であり; Ar3は、それぞれ、1個若しくは2個の同一若しくは異なるR6基で置換され た、Ph、Py、Fu、Th、Tz、Im又はPyrであり; Xは、OCH2、CH2O、S、S(O)又はS(O)2であり; R1は、H、低級アルキル、低級ペルフルオロアルキル、Ph、Py又はTz であり; R6はR4であり; 残りの置換基は請求項1に定義の通りである、請求項1に記載の化合物。 4. 式Ia: 〔式中、Ar3は、場合によってハロゲンで置換されたTh、Fu、Py、Tz 、Im、場合によって低級アルキルで置換されたPyr、又は場合によって1個 若しくは2個の同一若しくは異なるハロゲン原子又は1個のニトロ基で置換され たPhであり; Xは、OCH2、S、S(O)2又はS(O)であり; Yは、H又はFであり; Zは、N又はCHであり; R1は、低級アルキル、低級ペルフルオロアルキル、Ph,Tz,Im又はP yであり; R2は、H、低級アルキル又は低級ペルフルオロアルキルである〕 を有する、請求項1に記載の化合物。 5. 式Ib: 〔式中、Ar3は、Fu又はPhであり; Xは、CH2O、OCH2又はSであり; Yは、H又はFであり; Zは、N又はCHであり; R1は、低級アルキル、低級ペルフルオロアルキル又はTzであり; R2は、低級アルキル又は低級ペルフルオロアルキルであり; R3は、H又は低級アルキルである〕 を有する、請求項1に記載の化合物。 6. 式Ic: 〔式中、Ar3は、Fu又はPhであり; Yは、H又はFであり; R1は、H、低級アルキル、低級ペルフルオロアルキル、Ph、Py、Fu又 はTzであり; R2は、H、低級アルキル又は低級ペルフルオロアルキルであり; R3は、H又は低級アルキルである〕 を有する、請求項1に記載の化合物。 7. 式Id: 〔式中、Ar3は、Fu又はPhであり; R1は、低級ペルフルオロアルキル又はTzであり; R2は、低級アルキル又は低級ペルフルオロアルキルである〕 を有する、請求項1に記載の化合物。 8. 治療上有効量の請求項1に記載の化合物及び医薬上許容し得る担体を含む 医薬組成物。 9. 非ステロイド系抗炎症剤;末梢鎮痛剤;シクロオキシゲナーゼ阻害剤;ロ イコトリエン拮抗剤;ロイコトリエ ン生合成阻害剤;H1又はH2受容体拮抗剤;抗ヒスタミン剤;プロスタグランジ ン拮抗剤及びACE作動剤からなる群から選択される有効量の第2の有効成分を さらに含む、請求項8に記載の医薬組成物。 10. 第2の有効成分が非ステロイド系抗炎症剤である、請求項9に記載の医 薬組成物。 11. 前記第2の有効成分に対する前記請求項1に記載の化合物の重量比が、 約1000:1〜1:1000の範囲である、請求項10に記載の医薬組成物。 12. 請求項1、2、3、4、5、6又は7に記載の式(I)の化合物の医薬 上許容し得る塩。 13. SRS−A又はロイコトリエンの合成、作用又は放出の阻害に用いるた めの、請求項1、2、3、4、5、6又は7に記載の式(I)の化合物又はその 医薬上許容し得る塩。 14. 喘息の治療用薬剤の製造における、請求項1、2、3、4、5、6又は 7に記載の式(I)の化合物又はその医薬上許容し得る塩の使用。 15. ロイコトリエン生合成阻害剤としての、請求項1、2、3、4、5、6 又は7に記載の式(I)の化合物又は その医薬上許容し得る塩の使用。 16. 医薬上許容し得る担体と組み合わせた、許容し得るロイコトリエン生合 成阻害量の請求項1、2、3、4、5、6又は7に記載の式(I)の化合物を含 むロイコトリエン生合成阻害剤医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/330,036 US5552437A (en) | 1994-10-27 | 1994-10-27 | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
US330,036 | 1994-10-27 | ||
PCT/CA1995/000608 WO1996013500A1 (en) | 1994-10-27 | 1995-10-25 | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10507767A true JPH10507767A (ja) | 1998-07-28 |
Family
ID=23288032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8514209A Ceased JPH10507767A (ja) | 1994-10-27 | 1995-10-25 | ロイコトリエン生合成阻害剤としてのビスアリールカルビノール誘導体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5552437A (ja) |
EP (1) | EP0788497B1 (ja) |
JP (1) | JPH10507767A (ja) |
AT (1) | ATE201409T1 (ja) |
AU (1) | AU689656B2 (ja) |
CA (1) | CA2203417C (ja) |
DE (1) | DE69521054T2 (ja) |
ES (1) | ES2156961T3 (ja) |
WO (1) | WO1996013500A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527207A (ja) * | 2003-06-11 | 2006-11-30 | メルク フロスト カナダ リミテツド | 7−(1,3−チアゾール−2−イル)チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用 |
JP2008514661A (ja) * | 2004-10-01 | 2008-05-08 | エフ.ホフマン−ラ ロシュ アーゲー | ヘキサフルオロイソプロパノール置換エーテル誘導体 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19532714A1 (de) * | 1995-09-05 | 1997-03-06 | Bayer Ag | Kombination von 5-Lipoxygenase- und Leukotriensynthese Inhibitoren mit Glucocorticosteroiden |
US6097099A (en) * | 1995-10-20 | 2000-08-01 | Texas Instruments Incorporated | Electro-thermal nested die-attach design |
EP0836850A3 (en) * | 1996-10-17 | 2000-11-29 | Pfizer Inc. | Method of preventing allograft rejection |
KR100295206B1 (ko) * | 1998-08-22 | 2001-07-12 | 서경배 | 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물 |
ES2284817T3 (es) | 2001-01-26 | 2007-11-16 | Chugai Seiyaku Kabushiki Kaisha | Procedimientos para el tratamiento de enfermedades con inhibidores de la malonil coa descarboxilasa. |
CN101596191B (zh) | 2001-01-26 | 2011-06-15 | 中外制药株式会社 | 用作代谢调节剂的丙二酰基辅酶a脱羧酶抑制剂 |
ES2274005T3 (es) | 2001-01-26 | 2007-05-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidores de malonyl-coa decarboxilasa usados como moduladores metabolicos. |
BR0207408A (pt) | 2001-02-20 | 2004-02-25 | Chugai Pharmaceutical Co Ltd | Azóis como inibidores de malonil-coa decarboxilase úteis como moduladores metabólicos |
US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
EP1658071B1 (en) | 2003-08-01 | 2008-09-10 | Chugai Seiyaku Kabushiki Kaisha | Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors |
ATE400272T1 (de) | 2003-08-01 | 2008-07-15 | Chugai Pharmaceutical Co Ltd | Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer |
JP4727579B2 (ja) | 2003-08-01 | 2011-07-20 | 中外製薬株式会社 | マロニル−CoAデカルボキシラーゼ阻害剤として有用なシアノアミド化合物 |
ES2353306T3 (es) | 2003-08-01 | 2011-03-01 | Chugai Seiyaku Kabushiki Kaisha | Compuestos heterocíclicos útiles como inhibidores de la malonil-coa-descarboxilasa. |
DE602005023797D1 (de) * | 2004-07-14 | 2010-11-04 | Inflammation Res Ct Co Ltd | Verfahren zur Hemmung von Tumormetastasierung |
AR055041A1 (es) * | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
CA2624294A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
CA2636043A1 (en) * | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
MX344308B (es) | 2011-11-03 | 2016-12-13 | Merck Sharp & Dohme | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. |
CN109983022B (zh) | 2016-09-27 | 2022-06-07 | 默沙东公司 | 作为mGluR2负性别构调节剂的色满、异色满和二氢异苯并呋喃衍生物、组合物及其用途 |
CN107556201B (zh) * | 2017-09-08 | 2020-10-27 | 山西智创药研科技有限公司 | 一种制备间氨基苯酚的工艺方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089495A (en) * | 1989-01-30 | 1992-02-18 | Imperial Chemical Industries Plc | Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives |
IE70521B1 (en) * | 1989-02-28 | 1996-12-11 | Zeneca Pharma Sa | Heterocycles with inhibitory activity of 5-lipoxygenase |
EP0462830B1 (en) * | 1990-06-21 | 1995-10-18 | Zeneca Limited | Cyclic ether derivatives |
IE911853A1 (en) * | 1990-06-21 | 1992-01-01 | Ici Plc | Heterocyclene derivatives |
EP0505122A1 (en) * | 1991-03-21 | 1992-09-23 | Zeneca Limited | Alpha, alpha-dialkylbenzyl derivatives |
US5308852A (en) * | 1992-06-29 | 1994-05-03 | Merck Frosst Canada, Inc. | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis |
-
1994
- 1994-10-27 US US08/330,036 patent/US5552437A/en not_active Expired - Lifetime
-
1995
- 1995-10-25 AT AT95944792T patent/ATE201409T1/de not_active IP Right Cessation
- 1995-10-25 EP EP95944792A patent/EP0788497B1/en not_active Expired - Lifetime
- 1995-10-25 DE DE69521054T patent/DE69521054T2/de not_active Expired - Fee Related
- 1995-10-25 JP JP8514209A patent/JPH10507767A/ja not_active Ceased
- 1995-10-25 ES ES95944792T patent/ES2156961T3/es not_active Expired - Lifetime
- 1995-10-25 AU AU36957/95A patent/AU689656B2/en not_active Ceased
- 1995-10-25 WO PCT/CA1995/000608 patent/WO1996013500A1/en active IP Right Grant
- 1995-10-25 CA CA002203417A patent/CA2203417C/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527207A (ja) * | 2003-06-11 | 2006-11-30 | メルク フロスト カナダ リミテツド | 7−(1,3−チアゾール−2−イル)チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用 |
JP2008514661A (ja) * | 2004-10-01 | 2008-05-08 | エフ.ホフマン−ラ ロシュ アーゲー | ヘキサフルオロイソプロパノール置換エーテル誘導体 |
Also Published As
Publication number | Publication date |
---|---|
AU3695795A (en) | 1996-05-23 |
DE69521054T2 (de) | 2001-11-22 |
ATE201409T1 (de) | 2001-06-15 |
WO1996013500A1 (en) | 1996-05-09 |
EP0788497B1 (en) | 2001-05-23 |
CA2203417A1 (en) | 1996-05-09 |
CA2203417C (en) | 2007-10-02 |
AU689656B2 (en) | 1998-04-02 |
EP0788497A1 (en) | 1997-08-13 |
US5552437A (en) | 1996-09-03 |
ES2156961T3 (es) | 2001-08-01 |
DE69521054D1 (de) | 2001-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10507767A (ja) | ロイコトリエン生合成阻害剤としてのビスアリールカルビノール誘導体 | |
US5576338A (en) | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis | |
EP0788490B1 (en) | Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis | |
CN101657443B (zh) | 作为白三烯生物合成抑制剂的[1,2,3]三唑取代的喹啉和香豆素 | |
HRP930803A2 (en) | Fluorinated hydroxyalkylquinoline acids as leukortine antagonists | |
JPH0786101B2 (ja) | ロイコトリエン類の生合成阻害剤としての(キノリン―2―イルメトキシ)インドール類 | |
US5506227A (en) | Pyridine-substituted benzyl alcohols as leukotriene antagonists | |
US5308852A (en) | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis | |
JP2009504575A (ja) | 新規の置換された1,2,3,−トリアゾリルメチル−ベンゾチオフェン又は−インドール並びにロイコトリエン生合成阻害剤としてのそれらの使用 | |
US5424320A (en) | Heteroaryl coumarins as inhibitors of leukotriene biosynthesis | |
JP3594603B2 (ja) | ロイコトリエン拮抗薬としてのジアリール5,6−縮合複素環酸 | |
US5360815A (en) | Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis | |
JPS6160656A (ja) | ロイコトリエン拮抗剤 | |
US5252599A (en) | Heteroarylnaphthalene hydroxy acids as inhibitors of leukotriene biosynthesis | |
US5428060A (en) | Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis | |
JPH09504777A (ja) | ロイコトリエンアンタゴニストとしてのキノリン誘導体 | |
US5410054A (en) | Heteroaryl quinolines as inhibitors of leukotriene biosynthesis | |
US5426109A (en) | Phenylnaphthalene hydroxy acids | |
US5350744A (en) | Phenylnaphthalene lactones as inhibitors of leukotriene biosynthesis | |
JPH03501615A (ja) | 抗炎症活性を持つヘテロニ環式化合物 | |
CA2138631A1 (en) | 6,8 dioxabicyclo¬3.2.1|octanes as inhibitors of leukotriene biosynthesis | |
RO115954B1 (ro) | Derivati de chinolina, compozitie care ii contine, si metoda de tratament | |
JPS60115544A (ja) | ロイコトリエンきつ抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060324 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061010 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070409 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071030 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20080226 |